Brokerages Set Smith & Nephew plc (LON:SN) Target Price at GBX 1,439.67

Shares of Smith & Nephew plc (LON:SN) have received an average recommendation of “Hold” from the six research firms that are currently covering the company, MarketBeat reports. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 1 year target price among brokerages that have covered the stock in the last year is GBX 1,381.33.

Several equities analysts have commented on SN shares. JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of Smith & Nephew in a report on Friday, November 7th. Royal Bank Of Canada cut Smith & Nephew to a “sector perform” rating and lowered their price objective for the company from GBX 1,700 to GBX 1,350 in a research report on Wednesday. Citigroup raised their target price on Smith & Nephew from GBX 1,450 to GBX 1,600 and gave the stock a “buy” rating in a research report on Friday, October 31st. Finally, Panmure Gordon reiterated a “hold” rating and set a GBX 1,200 price target on shares of Smith & Nephew in a research note on Tuesday, December 9th.

Insider Activity at Smith & Nephew

In other news, insider Deepak Nath sold 1,240 shares of Smith & Nephew stock in a transaction dated Tuesday, November 11th. The shares were sold at an average price of GBX 1,257, for a total transaction of £15,586.80. Insiders own 0.19% of the company’s stock.

Smith & Nephew Stock Performance

Shares of SN opened at GBX 1,233.50 on Monday. The company has a debt-to-equity ratio of 70.22, a current ratio of 2.51 and a quick ratio of 0.84. The company’s 50 day moving average is GBX 1,291.09 and its 200-day moving average is GBX 1,260.36. The firm has a market capitalization of £13.52 billion, a price-to-earnings ratio of 44.41, a P/E/G ratio of 0.46 and a beta of 0.62.

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.